Audentes Therapeutics, Inc. - Oct 21, 2022 Form 3 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
10%+ Owner
Signature
/s/ Chad Diehl, Attorney-in-Fact, Astellas
Stock symbol
TSHA
Transactions as of
Oct 21, 2022
Transactions value $
$0
Form type
3
Date filed
10/31/2022, 04:05 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TSHA Common Stock 7.27M Oct 21, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are directly held by Audentes Therapeutics, Inc., a Delaware corporation, ("Audentes") a wholly owned direct subsidiary of Astellas US Holding, Inc., a Delaware corporation, ("Astellas US") which is in turn a wholly owned direct subsidiary of Astellas Pharma Inc., a corporation established under the laws of Japan ("Astellas"). Under SEC rules and regulations, each of Astellas and Astellas US may be deemed to have indirect beneficial ownership of the shares held by Audentes, which has direct beneficial ownership.

Remarks:

Exhibit List Exhibit 24.1 - Power of Attorney (Astellas) Exhibit 24.2 - Power of Attorney (Audentes)